JPMorgan Seeks Clarity On Dyne Therapeutics' DYNE-101 Expansion, Regulatory Path
JP Morgan analysts question Dyne Therapeutics' strategy for DYNE-101 in DM1, highlighting regulatory uncertainty and investor ...
Dyne Therapeutics (DYN) Gets a Buy from Scotiabank
In a report released today, Louise Chen from Scotiabank maintained a Buy rating on Dyne Therapeutics (DYN – Research Report), with a price ...
JPMorgan Chase & Co. Cuts Dyne Therapeutics (NASDAQ:DYN) Price Target to $17.00
Dyne Therapeutics (NASDAQ:DYN – Free Report) had its price objective decreased by JPMorgan Chase & Co. from $18.00 to $17.00 ...
Yahoo Finance8d
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with ...
Nasdaq8d
Dyne Therapeutics Appoints Erick J. Lucera as Chief Financial Officer to Support Late-Stage Clinical Programs
Dyne Therapeutics, Inc. announced the appointment of Erick J. Lucera as its new Chief Financial Officer, effective March 31, 2025. Lucera brings over 30 years of experience in the life sciences ...
Morningstar8d
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer
March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven ...